Join Growin Stock Community!

Jasper therapeutics, inc.JSPR.US Overview

US StockHealthcare
(No presentation for JSPR)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

JSPR AI Insights

JSPR Overall Performance

JSPR AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

JSPR Recent Performance

-2.90%

Jasper therapeutics, inc.

0.05%

Avg of Sector

-0.31%

S&P500

JSPR PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

JSPR Key Information

JSPR Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

JSPR Profile

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.

Price of JSPR

JSPR FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

JSPR Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.60
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
3.34
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.60
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
3.34
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is JSPR's latest earnings report released?

    The most recent financial report for Jasper therapeutics, inc. (JSPR) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating JSPR's short-term business performance and financial health. For the latest updates on JSPR's earnings releases, visit this page regularly.

  • How much cash does JSPR have?

    At the end of the period, Jasper therapeutics, inc. (JSPR) held Total Cash and Cash Equivalents of 51.32M, accounting for 0.89 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is JSPR's EPS continuing to grow?

    According to the past four quarterly reports, Jasper therapeutics, inc. (JSPR)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.13. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of JSPR?

    Jasper therapeutics, inc. (JSPR)'s Free Cash Flow (FCF) for the period is -17M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 18.66% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.